General
Preferred name
OXYBUTYNIN
Synonyms
OXYBUTYNIN CHLORIDE ()
Oxybutynin HCl ()
Oxybutinin ()
Oxybutynin hydrochloride ()
Oxibutyninum ()
Oxybutynine ()
Oxybutynin (chloride) ()
MJ4309-1 ()
NSC-759108 ()
Ditropan ()
MJ 4309-1 ()
Tropax ()
Gelnique ()
Pollakisu ()
Ditropan XL ()
MJ-4309-1 ()
5058 ()
Cystrin ()
Oxytrol ()
Contimin 2.5 ()
Oxytrol For Women ()
Promictuline ()
Urimin ()
Kentera (previously oxybutynin nicobrand) ()
Contimin 5 ()
Kentera ()
Lyrinel XL ()
Oxibutinina ()
Oxybutynin (hydrochloride) ()
Oxybutynin-d10 (hydrochloride) ()
P&D ID
PD009572
CAS
5633-20-5
119579-36-1
1508-65-2
120092-65-1
Tags
available
drug
Approved by
FDA
PMDA
First approval
1975
Drug indication
Discovery agent
Anticholinergic
Urinary incontinence
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA
Oxybutynin directly exerts an antispasmodic effect and inhibits the muscarinic acetylchloine action on the smooth muscle. By inhibiting particularily the M1 and M2 receptors of the bladder, detrusor activity is markedly decreased. Oxybutynin does not mediates its blocking effects at the skeletal neuromuscular junctions or autonomic ganglia.
PHARMACODYNAMICS
Oxybutynin is an antispasmodic and anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency by relaxing bladder smooth muscle. While oxybutynin exhibits one-fifth of the anticholinergic activity of [atropine] on the rabbit detrusor muscle, its antispasmodic activity is about four to ten times higher. Antimuscarinic activity resides predominantly in the R-isomer.
ROE
Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine.; Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.
DESCRIPTION
Oxybutynin is a racemic mixture of stereoisomers. We show the non-chiral molecule to represent the mixture. PubChem lists all 3 isomers here.
(GtoPdb)
DESCRIPTION
Muscarinic acetylcholine receptor antagonist
(LOPAC library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
2
Compound Sets
32
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Ki Database
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
72
Molecular Weight
357.23
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
7
Ring Count
2
Aromatic Ring Count
1
cLogP
3.34
TPSA
49.77
Fraction CSP3
0.59
Chiral centers
1.0
Largest ring
6.0
QED
0.6
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Muscarinic
Pathway
Neuroscience
GPCR/G protein
Membrane Transporter/Ion Channel
Neuronal Signaling
Target
mAChR
M1/M2/M3 antagonist
Potassium Channel
AChR
Member status
member
MOA
Muscarinic Antagonists
Source data
